Q-omics provides the consensus-scored CAMTA1-DT profile across patient tissues and cancer cell-line models. CAMTA1-DT expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CAMTA1-DT is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CAMTA1-DT RNA expression shows 16,794 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where CAMTA1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAMTA1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAMTA1-DT survival associations across molecular data types. CAMTA1-DT RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAMTA1-DT RNA expression–survival associations across cancer types. High CAMTA1-DT expression shows unfavorable associations in KIRC and ACC, but favorable associations in KIRP, OV, CESC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CAMTA1-DT RNA expression.
This table summarizes CAMTA1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CAMTA1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAMTA1-DT shows lower tumor expression in KIRC, KICH, THCA and KIRP and higher tumor expression in STAD and BLCA. The KIRC box plot shows higher CAMTA1-DT RNA expression in normal versus tumor tissue (log2 FC = −1.265, t-test p < 0.001).
This table shows molecular features associated with CAMTA1-DT in patient tissues and cancer cell lines. In patient samples, CAMTA1-DT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
